Selinexor, an oral selective inhibitor of nuclear export, targets exportin 1 (XPO1), a key mediator of cytoplasmic transport for tumor suppressor proteins, such as p53 and Forkhead box O. XPO1 overexpression has been observed in MM, making it a promising therapeutic target [9]. The gene discussed is XPO1; the disease is Miyoshi myopathy.